Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   2:42:15 PM EDT
133.03
-3.50 (-2.56%)
Products, Strategic Combinations, Other Pre-Announcement

Novartis Announces Collaboration With Alnylam On Liver-Targeted Therapy

Published: 01/06/2022 06:28 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Novartis Announces Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function.
Agreement Will Bring Alnylam's Proprietary Sirna Technology to Bear on Liver Target Identified by Novartis Researchers.
Novartis and Alnylam Have Agreed to Collaborate on Discovery and Development of Sirna-based Targeted Therapy to Restore Functional Liver Cells in Patients With End-stage Liver Disease.
Collaboration Aims to Develop Liver-targeted Therapy As a Potential Alternative to Transplantation for Patients Experiencing Liver Failure.
Further Company Coverage: .
((frankfurt.
Newsroom@thomsonreuters.
Com;)).